Second Study on Cardio-neuromodulation in Humans

Exclusion Criteria

• •Candidates will be excluded if ANY of the following criteria apply (detailed in Table 3):
• •\< 14 years of age;
• •Inability to provide consent;
• •Chronotropic negative medications (excepted in patients with a previous history of atrial fibrillation);
• •4 g amiodarone intake during the 2 months preceding enrollment;
• •Alternating right bundle branch block (RBBB) and left bundle branch block (LBBB), HV interval \> 70 ms;
• •LBBB, bifascicular block (RBBB + left anterior hemiblock \[LAHB\], RBBB + left posterior hemiblock \[LPHB\]);
• •PR interval permanently \> 240 ms;
• •Permanent AF, PAF or electrical cardioversion during the last 6 months;
• •Valvular or subvalvular aortic stenosis, mitral stenosis;
• •Any unstable medical condition, life expectancy \< 12 months;
• •Syncopes due a non-cardiac disease (excepted NMS) or advanced neuropathy;
• •Current pregnancy;
• •glaucoma.
• •Patients with transient atrioventricular conduction disturbances and normal atrioventricular conduction during an exercise test and normal QRS complexes are eligible for this study.
• •Patients with a high risk of bleeding are eligible, but clopidogrel (75 mg daily, 1 month of treatment) will then be preferred to oral anticoagulants.